asapiprant   Click here for help

GtoPdb Ligand ID: 11951

Synonyms: BGE-175 | BGE175 | example II-74 [US8153793B2] | S-555739
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Asapiprant (S-555739) is a DP1 receptor antagonist that was developed for anti-inflammatory potential [2]. It has been used in an animal model of COVID-19 to indicate that targeting the PLA2G2D-PGD2/DP1 receptor pathway provides some benefit in protecting aged mice from lethal virus infection [3]. A clinical study in a select subset of human COVID-19 patients is underway (as of April 2022).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 130.79
Molecular weight 501.16
XLogP 2.92
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OC(=O)COc1cc(ccc1c1ncco1)N1CCN(CC1)S(=O)(=O)c1ccc(cc1)OC(C)C
Isomeric SMILES CC(C)Oc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1cc(c(cc1)c1ncco1)OCC(=O)O
InChI InChI=1S/C24H27N3O7S/c1-17(2)34-19-4-6-20(7-5-19)35(30,31)27-12-10-26(11-13-27)18-3-8-21(24-25-9-14-32-24)22(15-18)33-16-23(28)29/h3-9,14-15,17H,10-13,16H2,1-2H3,(H,28,29)
1. Kugimiya A, Fujioka M, Tachibana Y, Murashi T. (2012)
Sulfonamide derivative having PGD2 receptor antagonistic activity.
Patent number: US8153793B2. Assignee: Shionogi and Co Ltd. Priority date: 27/09/2005. Publication date: 10/04/2012.
2. Takahashi G, Asanuma F, Suzuki N, Hattori M, Sakamoto S, Kugimiya A, Tomita Y, Kuwajima G, Abraham WM, Deguchi M et al.. (2015)
Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma.
Eur J Pharmacol, 765: 15-23. [PMID:26277322]
3. Wong LR, Zheng J, Wilhelmsen K, Li K, Ortiz ME, Schnicker NJ, Thurman A, Pezzulo AA, Szachowicz PJ, Li P et al.. (2022)
Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19.
Nature, 605 (7908): 146-151. [PMID:35314834]